Form 4: LGND Director Sells Shares Under 10b5-1 Plan

LIGAND PHARMACEUTICALS INC Director John W. Kozarich sold 467 shares of common stock on November 3, 2025, through a pre-arranged 10b5-1 trading plan.

Summary

• John W. Kozarich, a Director of LIGAND PHARMACEUTICALS INC (LGND), reported the sale of common stock.
• The transactions occurred on November 3, 2025, and involved multiple sales of LGND common stock.
• A total of 467 shares were sold across four separate transactions.
• These sales were executed pursuant to a written trading plan adopted by Mr. Kozarich on March 7, 2025, in accordance with Rule 10b5-1.
• Following these transactions, Mr. Kozarich beneficially owns 44,588 shares of LGND common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a pre-scheduled sale of common stock by a director under a Rule 10b5-1 plan, which is a routine disclosure and does not inherently convey positive or negative sentiment regarding the company's performance or prospects.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on immediate, non-public information, which enhances transparency and compliance.

Negatives

• The transactions resulted in a reduction of direct insider ownership by 467 shares, which some investors might perceive as a slight negative, even if pre-planned.

Future Outlook

This Form 4 filing is a disclosure of insider trading activity and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale of 467 shares by a director represents a minor reduction in insider ownership, which is generally a routine event when conducted under a Rule 10b5-1 plan and is unlikely to have a significant impact.

Next Steps

• The Reporting Person undertakes to provide the Registrant, any securityholder, or the SEC Staff, upon request, full information regarding the number of shares sold at each separate price within the reported ranges.

Key Dates

Keywords

LIGAND PHARMACEUTICALS, LGND, Form 4, Insider Trading, Stock Sale, Director, John W. Kozarich, 10b5-1 Plan